



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
02/715,272	06/14/71	PARTIER	12 2019

GENENTECH, INC.
ATTN: CAROLYN R. ADLER
460 POINT SAN BRUNO BLVD.
SOUTH SAN FRANCISCO, CA 94080

10M2/1021

EXAMINER	
ART UNIT	PAPER NUMBER

10M2/21

DATE MAILED:

10/21/73

Below is a communication from the EXAMINER in charge of this application

COMMISSIONER OF PATENTS AND TRADEMARKS

ADVISORY ACTION

THE PERIOD FOR RESPONSE:

is extended to run 4 months or continues to run _____ from the date of the final rejection
 expires three months from the date of the final rejection or as of the mailing date of this Advisory Action, whichever is later. In no event however, will the statutory period for the response expire later than six months from the date of the final rejection.

Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.

Appellant's Brief is due in accordance with 37 CFR 1.192(a).
 Applicant's response to the final rejection, filed 9/23/73 has been considered with the following effect, but it is not deemed to place the application in condition for allowance:
1. The proposed amendments to the claim and/or specification will not be entered and the final rejection stands because:
a. There is no convincing showing under 37 CFR 1.116(b) why the proposed amendment is necessary and was not earlier presented.
b. They raise new issues that would require further consideration and/or search. (See Note).
c. They raise the issue of new matter. (See Note).
d. They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.
e. They present additional claims without cancelling a corresponding number of finally rejected claims.

NOTE: The language "of a human immunoglobulin subgroup" has not been defined with respect to the variable domain of a consensus antibody.

2. Newly proposed or amended claims _____ would be allowed if submitted in a separately filed amendment cancelling the non-allowable claims.

3. Upon the filing an appeal, the proposed amendment will be entered will not be entered and the status of the claims will be as follows:

Claims allowed: None 12 and 13
Claims objected to: None
Claims rejected: 1 - 11, 17 - 21

DAVID L LACEY
SUPERVISORY PATENT EXAMINER
GROUP 180
10/11/73

However;

Applicant's response has overcome the following rejection(s): The rejection under 35 USC 112, first paragraph regarding "at least a portion" and "reasonably".

4. The affidavit, exhibit or request for reconsideration has been considered but does not overcome the rejection because The introduction of the language "human subgroup" is defined in part but not in the application. Also, it is not clear what it is referring to.
5. The affidavit or exhibit will not be considered because applicant has not shown good and sufficient reasons why it was not earlier presented.

The proposed drawing correction has has not been approved by the examiner.

Other

That the "consensus antibody" of the application would be identical to the antibody of Queen et al. The claim is not added with a different than that already

10M2/1021